CCM Biosciences Announces Launch of 5Prime Sciences Business Unit
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
MOUNT LAUREL, N.J. -- Businesswire -- Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com%2Fdiagnostic%2F%23intro&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=CCM+5Prime+Sciences&index=1&md5=aba71f3fe32095893ad1340655610c71) (5Prime) focused on the development and application of proprietary technology in the domain of DNA biotechnology. 5Prime’s technology platform (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com%2Fplatforms%2F%23enzyme-engineering-platform&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=technology+platform&index=2&md5=8c446d99a9e4ea246d1f9ae7abe59533) includes multiple patent-protected, globally commercialized compositions and methods for molecular cloning, next-generation DNA sequencing and molecular diagnostics.
5Prime has two focus areas: 1) in vitro diagnostic (IVD) tests: a wide array of companion diagnostics (CDx) tests (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com%2Fpipeline%2F&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=companion+diagnostics+%28CDx%29+tests&index=3&md5=562699e878c5163417320ac091f9cf08) for targeted cancer, rare disease, and prenatal/preimplantation diagnostics, developed using the droplet digital Polymerase Chain Reaction (ddPCR) and Next-Generation Sequencing (NGS) methodologies, which accompany the personalized medicine therapeutic (Rx) pipeline of CCM Bio; 2) synthetic biology: engineered DNA- and RNA-manipulating enzymes (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpmc-at.com%2Fenzyme_engineering_for_synthetic_biology_and_diagnostics.html&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=engineered+DNA-+and+RNA-manipulating+enzymes&index=4&md5=2fb0f0445e6c9e490111fe5f1b63ae99) that improve upon the enzymes used in IVD tests, in PCR reagents, and also in enzymatic DNA/RNA synthesis.
Proven technology behind market-leading DNA sequencing products and diagnostic tests; including one of the 5 highest revenue-generating technologies invented in the history of Princeton University
Focus areas 1 and 2 are based on the company’s patented technology (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpmc-at.com%2Ftechnologies.htm&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=company%26%238217%3Bs+patented+technology&index=5&md5=f70bbcabc5c0b4282e688d2ae212bb7f) originating in the PhD thesis work of Co-Founder and CEO Dr. Raj Chakrabarti at Princeton University. According to the Princeton University Office of Technology Licensing, patents in this portfolio, which are now controlled by 5Prime, are among the top 5 revenue-generating patents in the history of the university, having been commercialized in collaboration with companies (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fpmc-at.com%2Fcompanies.htm&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=commercialized+in+collaboration+with+companies&index=6&md5=945fd7342c2c3f9340aec690487cd074) such as Celera Diagnostics, Quest Diagnostics, Abbott, New England Biolabs, and Toyobo Life Sciences. Diagnostic tests and products based on the company’s intellectual property include the XSense test from Quest Diagnostics, which is the leading DNA-based carrier screening test for autism (Fragile X syndrome); and the Q5 polymerase kit marketed by New England Biolabs, which is the leading high-fidelity polymerase kit for DNA sequencing.
In the context of molecular diagnostics, NGS is typically applied to diagnose in high-throughput the patterns of DNA mutations in genes. A related method called RNA-Seq, which applies NGS to RNA rather than DNA to measure real-time gene expression levels, has emerged as a foundation for modern personalized medicine. However, a notorious difficulty in both traditional NGS and RNA-Seq is sequence bias, which results in inaccurate estimates of the relative copy numbers of different genes and associated disease-causing mutations, and which has limited the transformative potential of these methods. ddPCR is a sensitive method for diagnosing mutations in specific disease-associated genes that is also limited by problems of sequence bias.
5Prime’s technology enables the efficient polymerization and amplification (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.dropbox.com%2Fs%2Fz7phwugtvvthbmt%2FCelera%2520Patent.pdf%3Fdl%3D0&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=efficient+polymerization+and+amplification&index=7&md5=211f450864d1fa9fec2456c0b2ebec19) of nearly any DNA or RNA sequence to overcome sequence bias in nucleic acid amplification and associated diagnostic methods like NGS and ddPCR, the global markets for which were valued at $10B and $6B, respectively, in 2022 and expected to surpass $44B and $14B, respectively, by 2032. Its state-of-the-art synthetic biology platform for polymerase enzyme engineering generates proprietary polymerases with optimal properties for NGS or PCR-based diagnostic tests, by applying machine learning algorithms to the big data generated from ultrahigh-throughput, microfluidic experimental screening of enzyme activity (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fccm-bio.com%2Fplatforms%2F%23enzyme-engineering-platform%3A%7E%3Atext%3DTHROUGHPUT%2520DROPLET%2520MICROFLUIDICS-%2CDROPLET%2C-MICROFLUIDICS%253A%2520FURTHER%2520DETAILS&esheet=53874570&newsitemid=20231227408478&lan=en-US&anchor=machine+learning+algorithms+to+the+big+data+generated+from+ultrahigh-throughput%2C+microfluidic+experimental+screening+of+enzyme+activity&index=8&md5=a4632f546549fd3e9fabc024d39cee46). In addition, the company’s technology platform applies proprietary nonaqueous media and computational systems biology methods in conjunction with such enzymes to dramatically improve nucleic acid polymerization and amplification efficiency.
About CCM Biosciences
CCM Biosciences, Inc. is a biotechnology company dedicated to discovering and developing novel drugs - including small molecules, gene therapies, biologics, and nanomedicines - as well as associated companion diagnostics. CCM Bio’s patented molecular discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, American Chemical Society journals and Nature Publishing Group journals. CCM Bio is partnered with the global chemical and pharmaceutical services company PMC Group, Inc. for fully integrated discovery, development and manufacturing of drugs and diagnostics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231227408478/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:CCM Biosciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 서울 평창동 이엔갤러리, 남재현 작가 ‘Moon Over September’ 개인전 개최 - 뉴스와이어
- SAS코리아, 이중혁 신임 대표이사 선임 - 뉴스와이어
- 항공안전기술원, 드론 실증도시 구축사업으로 지자체별 지역 특성 맞춤형 드론 활용 서비스 지
- 대웅제약, 숙취해소제 ‘에너씨슬 퍼펙트샷 쎈’ 출시 - 뉴스와이어
- LIG넥스원, 이라크와 중거리 지대공 유도무기 ‘천궁II’ 공급계약 체결 - 뉴스와이어
- 한국지역난방공사, 2024년도 신입직원 68명 임용 - 뉴스와이어
- 테바소프트 ‘2024 에듀테크 코리아 페어’ 참가… AI 기반 감정 교육 솔루션 공개 - 뉴스와이어
- 두구다, 중기부 ‘팁스’ 선정… AI 기반 의료 경영 최적화 솔루션 ‘메디버니’ 개발 본격화 -
- GC녹십자, 혈우병 환자 개인맞춤형 소프트웨어 ‘WAPPS-HEMO’ 업그레이드 출시 - 뉴스와이어
- 인천창조경제혁신센터-대한항공, 항공우주산업 분야 오픈이노베이션 사업설명회 개최 - 뉴스와